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Background: Vasohibin-2 (VASH2) has been identified as an endogenous and vascular endothelial growth factor
(VEGF)-independent angiogenic factor that is highly expressed in tumor cells. In the present study, we aimed to
determine whether pre-existing vascular changes can be used to predict tumor transformation as benign or
malignant. We sought to characterize microvascular changes and tumor development in the intestinal tract of
ApcMin/+ mice and ApcMin/+/Vash2−/− mice.
Methods: ApcMin/+ mice provide a unique orthotopic model for the development of spontaneous adenomatous
polyposis and subsequent carcinomas, a phenomenon termed the adenoma-carcinoma sequence. ApcMin/+ mice
were mated with Vash2−/− mice with a mixed C57BL/6 background and the resulting pups were screened for the
Min mutation and for the Vash2−/− gene by PCR. Intestinal tumors from ApcMin/+ mice and ApcMin/+/Vash2−/− mice
were removed and either frozen or epon-embedded for subsequent analyses. For 3-dimensional imaging using
confocal laser-scanning microscopy and transmission electron microscopy, cryosections were made, and immuno-
fluorescent staining for various markers was performed.
Results: We found that structural abnormalities in tumor vessels from benign tumors resembled those in malignant
tumors. In addition, a novel angiogenic factor, vasohibin-2 (VASH2) protein, was detected around tumor blood
vessels in late-stage adenomas and adenocarcinomas, but was absent from early-stage adenomas in ApcMin/+ mice.
Tumors used to examine endogenous VASH2 (derived from CMT93 colon carcinomas) were less vascularized in
Vash2−/− mice and were more regular than those seen in wild-type (WT) mice. In addition, tumors in Vash2−/− mice
were smaller than those in WT mice. Furthermore, cross-breeding of mice homozygous for a deletion of Vash2 with
mice heterozygous for the APC mutation resulted in animals that showed a significant decrease in the number of
polyps in the small intestine.
Conclusion: We propose that VASH2 may modulate the onset of tumors in the gastrointestinal tract by regulating
tumor angiogenesis.
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Angiogenesis, the formation of new blood vessels, is an
essential physiological process in embryo development,
normal growth, and tissue repair, and is tightly regulated
at the molecular level. Dysregulation of angiogenesis oc-
curs in various pathological conditions and is one of the
hallmarks of cancer [1,2]. Recognition of the role of
angiogenesis during neoplastic development is important
for a more comprehensive understanding of the mecha-
nisms involved in tumor growth and metastasis [3-5].
Tumor vessels are histopathologically different from
normal vessels; most tumor vessels have irregular diame-
ters, abnormal branching patterns, and do not fit well
into the usual categorization of arterioles, capillaries, or
venules [6-8]. Moreover, the endothelial cells (ECs) that
make up tumor vessels are often loosely interconnected
and have intercellular openings and abnormal pericytes,
contributing to the leakiness of these vessels [9-11].
Structural abnormalities in the basement membrane of
tumor vessels are also responsible for their relative im-
maturity in comparison with normal vessels [12,13].
Although the main purpose of tumor angiogenesis is
to maintain blood supply to the tumor, the process
usually occurs in an abnormally regulated fashion and the
resulting tumor vasculature may have abnormal organization,
structure, and function [1]. Recent advances have led to a
better understanding of the vascular changes in malignant
tumors, but the structural abnormalities in blood vessels
of benign tumors (pre-neoplastic lesions) and those
present during malignant transformation are still poorly
understood.
Angiogenesis is regulated by highly coordinated func-
tions of various proteins that play pro- or anti-angiogenic
roles [14]. Pro-angiogenic factors include vascular endo-
thelial growth factor (VEGF), fibroblast growth factor,
platelet-derived growth factor, insulin-like growth factor,
transforming growth factors, angiopoietins, and several
chemokines, while anti-angiogenic factors include throm-
bospondin-1, angiostatin, and endostatin [15]. Two novel
endogenous paracrine factors, termed vasohibins, have
also been described recently [16]. Vasohibin-1 is anti-an-
giogenic, while vasohibin-2 appears to be pro-angiogenic.
Vasohibin-2 (VASH2) is mainly expressed by infiltrating
bone marrow-derived mononuclear cells at the angioge-
nic-sprouting front [16-20], and the expression of VASH2
in human serous ovarian adenocarcinoma and hepatocel-
lular carcinoma accelerates tumor growth by promoting
angiogenesis [21,22]. However, it is not known if there are
differences in VASH2 expression between tumor cells
and tumor-associated ECs. In addition, although VEGF-
targeted therapy shows promise for the inhibition of
angiogenesis during tumor progression, new therapeutic
targets are needed to advance anti-angiogenic treatments
in cancer. Therefore, the development of novel therapeuticagents may be facilitated by identification and characteri-
zation of new angiogenic factors, and this may be achieved
using spontaneous tumor models [22].
Elucidation of the angiogenic patterns in benign tu-
mors and the involvement of various pro- and anti-
angiogenic factors are important for understanding the
development of malignant tumors and the neoplastic
transformation sequence in intestinal epithelia [23,24].
In the current study, relationships between tumor angio-
genesis and multi-step carcinogenesis were assessed
using the ApcMin/+ mouse model, which spontaneously
develops multiple intestinal adenomas that mimic those
that undergo early transformation into adenocarcinomas
in patients with familial adenomatous polyposis [25].
Using this mouse model offers the advantage of close re-
capitulation of the histopathological characteristics ob-
served in human cancer. Furthermore, tissue-specific
induction of mutations gives rise to orthotopic tumors
in the context of a functional, immune-competent
microenvironment, and thus includes the crosstalk be-
tween an emerging tumor and its environment [26-28].
In the present study, we sought to characterize the
microvascular changes that occur during the adenoma-
carcinoma sequence in a tumor to determine whether
pre-existing vascular changes can be used to predict
tumor transformation from benign to malignant. For com-
parison, wild-type (WT) C57BL/6 mice and Vash2−/− mice
bearing transplanted syngeneic CMT93 colorectal carcin-
oma cells were included in the study. The effects of
VASH2 on adenoma growth and progression to carcin-
omas were also examined by cross-breeding mice with a
complete absence of Vash2 expression (Vash2−/− mice)
with ApcMin/+ mice. Our results indicate a novel role for
VASH2 in tumor angiogenesis as an index of malignant
transformation and suggest that VASH2 may be a novel
target for anti-angiogenic agents in cancer therapy.
Results
Functional changes in local vascular networks during the
adenoma-carcinoma sequence
To understand the process of neovascularization in solid
spontaneous tumors, the relationship between tumor pro-
gression and tumor vessel formation during the adenoma-
carcinoma sequence was examined using tomato lectin
and immunohistochemistry (Figure 1). Adenoma and
adenocarcinoma were recognizable macroscopically in the
intestine (Figure 1A) and in hematoxylin and eosin
(H&E)-stained specimens (Figure 1B). Abnormal tumor
vessels formed in adenomas were highly dilated compared
with normal intestinal vessels (Figure 1C). Additionally,
abnormally shaped new tumor vessels appeared rapidly
in the adenoma. Although the vascularized areas in
the tumor became wider and the density of the tumor ves-
sels increased as tumors grew and progressed towards
Figure 1 (See legend on next page.)
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Figure 1 Relationship between tumor progression and local microvascular changes during multistep carcinogenesis in ApcMin/+ mice.
A, Representative images of normal intestine or intestinal polyps: normal region (left), adenoma (center), adenocarcinoma (right). n = 20. B, H&E
staining of adenoma and adenocarcinoma. Scale bars: 100 μm. C, Tomato lectin-labeled vascular architecture in a normal region, adenoma, and
adenocarcinoma. Note the marked structural abnormalities in the tumor vessels, including altered vascular density, vessel compression, uneven
diameter, blind ending vessels, and leakiness (arrowheads) in adenocarcinoma. Blood vessels in adenoma and adenocarcinoma lost their vascular
hierarchy. Scale bars: 100 μm. D, Double-staining for FITC-tomato lectin and type IV collagen in a normal region, adenoma and adenocarcinoma
during the adenoma-carcinoma sequence. Scale bars: 100 μm. E, Pericyte distribution in tumor vessels during the adenoma-carcinoma sequence
in ApcMin/+ mice. Vessels in a normal region of the small intestine, adenomas, and adenocarcinomas. Vessels were stained with FITC-tomato lectin
(green). Pericytes were visualized with a combination of α-SMA (red) and desmin (blue). Scale bars: 20 μm.
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the outside of the tumors. Leakiness of tumor vessels was
also seen in adenocarcinoma. In contrast, leakage of lectin
from blood vessels was not observed in normal tissue or
in adenoma (Figure 1C).Morphological changes of the vascular walls in adenoma
and adenocarcinoma
To illustrate the histopathological basis of the changes
observed during the sequence of malignant changes,
basement membranes outlined by type IV collagen in
benign intestinal tumors were compared with those in
malignant intestinal tumors from ApcMin/+ mice. Lectin
staining extended clearly beyond the basement mem-
branes of the blood vessels in the tumors. As the tumors
became malignant, the irregularity of the epithelial
framework became more prominent (Figure 1D). More-
over, triple fluorescent staining for tomato lectin, desmin,
and α-smooth muscle actin (α-SMA) in normal intestinal
tissue, adenoma, and adenocarcinoma (Figure 1D) re-
vealed that α-SMA-positive pericytes, which were absent
in normal capillaries [9], were clearly present in both ad-
enoma and adenocarcinoma samples. These results indi-
cate that the blood vessels in pre-neoplastic lesions
(benign tumors) already exhibit malignant patterns.Ultrastructure of newly developed tumor vessel
endothelial cells in adenoma and adenocarcinoma
The ultrastructure of blood vessel ECs was examined
during the adenoma-carcinoma sequence in ApcMin/+
mice. Compared with normal blood vessels (Figure 2A),
abnormal microvilli and membrane projections were ob-
served in adenoma and adenocarcinoma tumor blood
vessels (Figure 2B and C). Marked structural changes in
the microvasculature were found in the microvilli of
benign tumors (Figure 2B). As the tumors became ma-
lignant, the irregularity of microvilli in the tumor endo-
thelium became more prominent and more frequent
(Figure 2C), and ECs accumulated lipid droplets in
adenocarcinomas. At the same time, the basement mem-
brane of tumor vessels became more multi-layered in
adenoma and adenocarcinoma, compared with normal
vessels (Figure 2D).Angiogenic features of local microvessels in adenoma
and adenocarcinoma
Next, we compared differences in the densities of micro-
vessels per field between normal tissue and adenoma or
adenocarcinoma in ApcMin/+ mice by measuring the total
area of the vessels at each stage (Figure 3A). The dens-
ities of CD31-positive vessels were significantly greater
in adenoma and adenocarcinoma than in normal tissues
in ApcMin/+ mice (Figure 3A). Moreover, the densities of
Von Willebrand factor (vWF)-positive vessels were sig-
nificantly greater in adenoma and adenocarcinoma than
in normal tissues in human specimens (Figure 3B).
These results show that the microvascular densities of
human adenoma and adenocarcinoma were similar to
those of ApcMin/+ mouse tumors (Figure 3).
Few studies have reported the mRNA expression of
endothelial markers and angiogenic factors in benign
tumors. We therefore performed real-time PCR analysis
of normal intestinal tissues or intestinal polyps isolated
from WT mice or ApcMin/+ mice (Additional file 1:
Figure S1). These data showed significant increases in
the expression of CD31 and CD105 in intestinal polyps
from ApcMin/+ mice compared with normal intestinal tis-
sues from WT and ApcMin/+ mice. The expression of
CD105 in intestinal polyps from ApcMin/+ mice was also
significantly increased in comparison with that in WT
mice. In contrast, no significant changes in the expres-
sion of Vegfa were observed among all the groups.
Vash2 expression in tumor blood vessels and during
malignant transformation
Unlike VEGF and other angiogenic factors, VASH2 is an
endogenous and VEGF-independent angiogenic factor
that is highly expressed in bone marrow-derived mono-
nuclear cells and tumor cells, but only weakly expressed
in ECs [19,21]. Its role in tumor angiogenesis is unknown,
but it is likely that VASH2 functions via mechanisms that
are distinct from those of VEGF [16]. Therefore, we
examined the expression of VASH2 during the malignant
transformation sequence in ApcMin/+ mice. The level of
Vash2 mRNA increased during malignant transformation
(Figure 4A). Moreover, VASH2 protein was detected
around tumor blood vessels in late-stage adenomas and
adenocarcinomas, while early-stage adenomas stained
Figure 2 (See legend on next page.)
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Figure 2 Ultra-thin transmission electron microscope sections showing morphological changes in blood vessels during the adenoma-
carcinoma sequence in ApcMin/+ mice. A, A vessel in a normal region. The luminal surface of the endothelium generally has a smooth contour,
but the thin margins of adjacent cells may overlap slightly and the distance to the lumen is short. Asterisks, endothelial cells; arrows, marginal
fold at the cellular edge. Scale bars: 2 μm. B, Adenoma. Marked structural changes in the microvasculature were observed in aberrant villi of
benign tumors that lacked endothelial cell junctions. Asterisks, endothelial cells; arrowheads, abnormal microvilli. Scale bars: 2 μm. C, Adenocarcinoma.
The morphology of the vascular luminal surface became irregular; the endothelial cells accumulated lipid droplets and the irregularity of tumor vessels
in terms of size variation became more prominent. Asterisks, endothelial cells; arrowheads, abnormal microvilli; double arrowheads, lipid droplet. Scale
bars: 4 μm (left), 1 μm (right). D, Ultra-thin sections showing morphological changes in the basement membrane. Note the multi-layered basement
membranes in adenoma and adenocarcinoma. Asterisks, endothelial cells; double arrows, a layer of the basement membrane. Scale bars: 0.5 μm.
Kitahara et al. Molecular Cancer 2014, 13:99 Page 6 of 15
http://www.molecular-cancer.com/content/13/1/99negative for VASH2 in ApcMin/+ mice (Figure 4B
and C). In addition, the expression of VASH2 was
detected in tumor cells from adenocarcinomas
(Figure 5C).
Effects of Vash2-knockout on tumor growth and
angiogenesis in C57BL/6 mice
VASH2 protein was detected around tumor blood vessels in
late-stage adenoma and adenocarcinoma in ApcMin/+ mice.
These findings suggested that the expression of VASH2
might contribute to malignant transformation during the
adenoma-carcinoma sequence. Thus, to clarify the function
of endogenousVASH2, we examined whether tumor growth
and tumor angiogenesis were altered in Vash2−/− mice.
CMT93 tumors expressing VASH2 were implanted by
injecting WT and Vash2−/− C57BL/6 mice with 2.5 × 106
cells (Additional file 2: Figure S2 and Figure 5). Tumors in
Vash2−/− mice were less vascularized and blood vessels ap-
peared more normal than those inWTmice (Figure 5A and
B). In addition, tumors in Vash2−/− mice were smaller than
those inWTmice (Figure 5C).Figure 3 Comparison of vascular density and angiogenic patterns be
Vascular density and angiogenic patterns of normal intestine and tumor tis
field between normal tissue and adenoma or adenocarcinoma in ApcMin/+
each stage. The MVD was estimated by measuring the total areas of norma
of normal small intestine, mouse adenoma, or mouse adenocarcinoma at a
angiogenic patterns of normal human intestine and colon tumor specimen
vessels in 10 separate fields of normal colon, human adenoma, or human a
(H&E) staining of adenocarcinoma in human specimens and staining for vW
Scale bar: 100 μm.VASH2 modulates tumor onset in the gastrointestinal
tract of ApcMin/+/Vash2−/− mice
To investigate the possible roles of VASH2 in intestinal
tract tumorigenesis, ApcMin/+ mice were crossed with
Vash2−/− mice to generate ApcMin/+/Vash2−/− mice
(Figure 6A). Polyp numbers were then compared between
ApcMin/+ mice and ApcMin/+/Vash2−/− mice (Figure 6B
and C). The number of small intestinal polyps was signifi-
cantly reduced in ApcMin/+/Vash2−/− mice at 16 weeks of
age compared with ApcMin/+ mice (Figure 6C). Histologi-
cally, all polyps in ApcMin/+/Vash2−/− mice were adenomas
or adenocarcinomas, similar to those in ApcMin/+ mice.
To determine the relationship between VASH2 sup-
pression and intestinal polyposis, we assessed Vash2
mRNA levels in the intestinal mucosa and polyps. Be-
cause we had inserted a β-galactosidase gene (LacZ) into
the Vash2 knockout allele, we monitored Vash2 pro-
moter activity by LacZ expression (Figure 6D). Strong
X-gal staining was observed in the crypt of the normal
small intestine and in tumor cells in adenoma or adeno-
carcinoma in ApcMin/+/Vash2−/− mice. These resultstween mouse intestinal polyps and human surgical specimens. A,
sues in ApcMin/+ mice. The difference in density of microvessels per
mice was compared by measuring the total area comprising vessels at
l blood vessels and newly formed blood vessels in 10 separate fields
magnification of 600 ×. *P < 0.05, **P < 0.01. B, Vascular density and
s. The MVD was estimated by measuring total areas comprising blood
denocarcinoma at a magnification of 600 ×. Hematoxylin and eosin
F, a marker for human endothelial cells, in adenocarcinoma. **P < 0.01.
Figure 4 Expression of VASH2 protein in tumors during the adenoma-carcinoma sequence. A, Normal intestinal tissue or intestinal polyps
were examined for Vash2 expression by RT-PCR. Total RNA was isolated from normal intestinal tissue in C57BL/6 mice and ApcMin/+ mice or from
intestinal polyps in ApcMin/+ mice. All samples were normalized to Gapdh and are expressed as relative ratios to wild-type (WT) controls. Note
the increase in Vash2 levels in late-stage adenoma and adenocarcinoma in ApcMin/+ mice. *P < 0.05, **P < 0.01, n = 3. B, H&E staining of late-stage
adenoma in ApcMin/+ mice and double-immunostaining of tomato lectin and VASH2 for detection of tumor vessels in the same region. Scale bar:
200 μm. C, A high magnification image of CD31 staining in adenocarcinoma, showing VASH2 expression around tumor vessels. Note that VASH2
expression was only found around these vessels in adenocarcinoma. Center inset, control staining with a nonspecific IgG. Right inset, higher
magnification of tumor cells shown in D. Scale bar: 50 μm, 30 μm (right inset).
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polyposis in the small intestine of ApcMin/+ mice.
VASH2 regulation of tumor blood vessels in polyps from
ApcMin/+/Vash2−/− mice
To understand the role of VASH2 in tumor vessels, we
compared the histopathological abnormalities of tumor
vessels in ApcMin/+ mice and ApcMin/+/Vash2−/− mice. Ab-
normal vascular networks appeared in tumors and were
highly dilated compared with normal vessels (Figure 7A).
However, tumor blood vessels in ApcMin/+/Vash2−/− mice
had more pericyte coverage compared with ApcMin/+
mice (Figure 7B-D). In contrast, some tumor lesions in
ApcMin/+/Vash2−/− mice were less vascularized than hyper-
plastic lesions in the polyps (Figure 8).
Discussion
In this study, we sought to characterize microvascular
changes in the intestine of ApcMin/+ mice, a useful
animal model for studying spontaneous adenomatous
polyposis and subsequent adenocarcinoma (a process
termed as the adenoma-carcinoma sequence) [24,25].
We found that changes in local vascular networks
reflected the neoplastic transformation sequence of the
intestinal epithelia, as follows: First, both structural and
functional changes in local vascular networks had
already been initiated in benign tumors in ApcMin/+mice, and in corresponding human surgical specimens.
Second, the pattern of tumor angiogenesis in benign tu-
mors was similar to that in malignant tumors. Third,
VASH2 expressed in the adenocarcinoma cells promoted
tumor growth and tumor angiogenesis in ApcMin/+ mice.
Based on these data, we propose that the sequence of
phases during tumor transformation from benign to ma-
lignant is based on microvascular changes, as summa-
rized in Table 1.
Morphological changes in blood vessels occurred earl-
ier than malignant changes in the epithelium of intes-
tinal lesions. This suggests that angiogenesis patterns
may play a critical role in the development and growth
of benign tumors during multi-step carcinogenesis.
There is increasing evidence that angiogenesis may also
play a critical role in development of benign tumors
[29-32]. Although angiogenesis is tightly regulated at the
molecular level, dysregulation of angiogenesis is a hall-
mark of cancer and can lead to various pathological con-
ditions [33]. The imbalance of pro- and anti-angiogenic
signaling within tumors creates an abnormal vascular
network that is characterized by dilated, tortuous, and
hyperpermeable vessels [34]. The physiological conse-
quences of these vascular abnormalities include tem-
poral and spatial heterogeneity in tumor blood flow and
oxygenation and increased interstitial fluid pressure in
tumors [35,36]. These abnormalities and the resulting
Figure 5 Tumor progression and tumor angiogenesis in Vash2 KO mice. A, Tomato lectin staining of tumor vessels in CMT93 tumor-bearing
WT mice (left) and Vash2−/− mice (right). Scale bars: 100 μm. Compared with CMT93 tumors in WT mice, the number of tumor vessels markedly
decreased in tumors of Vash2−/− mice. B, Microvascular density (MVD) was estimated by measuring the total area comprising CD31+ blood
vessels in three separate fields of CMT93 tumors in WT mice or Vash2−/− mice at 400× magnification. *P < 0.05, n = 8. C, Growth of CMT93
tumors transplanted into WT or Vash2−/− mice. Open columns represent CMT93 tumor-bearing WT mice and closed columns represent CMT93
tumor-bearing Vash2−/− mice. *P < 0.05, n = 15.
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to a reduction in the efficacy of chemotherapy, radio-
therapy, and immunotherapies [37]. However, none of
these previous studies have demonstrated that both
structural and functional changes in blood vessels during
multi-step carcinogenesis reflect the neoplastic trans-
formation sequence of epithelia and the degree of malig-
nancy, as we observed in this study. We were able to
show changes in tumor vessels during multistep carcino-
genesis in spontaneous tumors as a whole vascular net-
work using fluorescent 3D imaging and transmission
electron microscopy. These results showed that the
histopathology of the vasculature in late stage adenoma
was similar to that of malignant tumors.
VASH1 is expressed in ECs in the termination zone, sup-
pressing angiogenesis, whereas VASH2 is expressed mainly
in infiltrating bone marrow-derived mononuclear cells at
the sprouting front, promoting angiogenesis [16,19]. How-
ever, exogenous VASH2 exhibits anti-angiogenic activity in
the mouse cornea [17]. VASH2 expression has been dem-
onstrated in certain ovarian cancers, where it promotestumor growth and peritoneal dissemination of tumor cells
by stimulating tumor angiogenesis [21]. VASH2 is also
highly expressed in hepatocellular carcinoma cells (HCCs)
and tissues, and promotes HCC angiogenesis and malignant
transformation [22]. In our study, VASH2 was mainly
expressed by late stage adenoma and spontaneous adeno-
carcinoma cells around tumor vessels in ApcMin/+ mice.
Transplanted CMT93 tumors in Vash2−/− mice were less
vascularized and more regular than those in WT mice. Fur-
thermore, in gastrointestinal tumors of ApcMin/+/Vash2−/−
mice, the number of small intestinal polyps was significantly
reduced, pericyte coverage of tumor vessels was increased,
and tumor lesions were less vascularized than hyperplasia
lesions. These results support the hypothesis that VASH2
plays an important role in tumor angiogenesis and tumor
progression. Because inhibition of VASH2 normalized ab-
normal tumor vessels in adenocarcinoma, VASH2 may be
an important therapeutic target in the treatment of human
cancers.
Control of angiogenic factors such as VASH2 at stages
of benign tumorigenesis may inhibit malignant
Figure 6 Tumor onset in the intestinal tract of ApcMin/+/Vash2−/− mice. A, Genomic DNA samples isolated from mouse tails were genotyped by
PCR using primers that detect both WT and mutant alleles of Apc Min/+ or Vash2. B, Dissection micrographs of the small intestine from ApcMin/+ mice
(left) and ApcMin/+/Vash2−/− mice (right) at 16 weeks of age. C, Polyp numbers in the small intestine in ApcMin/+ mice (open column) or ApcMin/+/Vash2
−/− mice (closed column) at 16 weeks of age. **P < 0.01, n = 8. D, LacZ activity in ApcMin/+mice, ApcMin/+/Vash2+/− mice and ApcMin/+/Vash2−/− mice.
Expression of LacZ was not seen in ApcMin/+ mice or in ApcMin/+/Vash2+/− mice. Note the marked LacZ expression in crypts (arrows) and tumor cells
in ApcMin/+/Vash2−/− (arrowheads). Line, tumor area.
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agents such as anti-VASH2 neutralizing antibodies could
be developed to suppress changes in local vascular net-
works, the intestinal epithelium may not become malig-
nant during the adenoma-carcinoma sequence. Thus,
the findings of this study may contribute to the develop-
ment of new antivascular agents as prophylactic medi-
cines for malignant cancers. In addition, we propose that
the microcirculation may act as an index of malignant
transformation and may have potential use in future
diagnosis and treatment of cancer. A better understand-
ing of the various mechanisms of angiogenesis will facili-
tate development of novel anti-vascular therapies for the
treatment of malignant tumors.
Conclusions
We observed that angiogenic patterns were altered in
pre-neoplastic intestinal lesions during the early stages
of carcinogenesis, i.e., prior to the switch from adenoma
to adenocarcinoma. The up-regulation of VASH2 in ad-
enoma may induce the observed changes in vascular
architecture, similar to those observed in malignant
tumors. We conclude that several events such as “tumor
angiogenesis” and the “malignant angiogenic switch”
(summarized in Table 1) occur before transformation to
carcinoma and are likely to reflect the continuousprocess of cancer development. We are currently investi-
gating the possibility that this interaction also applies to
other tumor models. Moreover, to provide a more com-
prehensive understanding of the angiogenic mechanisms
of VASH2, further studies using ApcMin/+ / Vash2−/−
double-transgenic mice are underway. Further delinea-
tion of the role of VASH2 in tumor angiogenesis may
lead to novel strategies in anti-tumor therapy.
Methods
Mice
C57BL/6 J-ApcMin/+ (ApcMin/+) of both sexes were pur-
chased from the Jackson Laboratory (Bar Harbor, ME)
and male C57BL/6 (wild type: WT, MHC class I type:
H-2b) were purchased from Japan SLC Inc. (Shizuoka,
Japan). Vash2 knockout (Vash2−/−) mice were generated
as described elsewhere [19]. ApcMin/+ mice of a pure
C57BL/6 background were mated to Vash2−/− mice of a
mixed C57BL/6 background, and the resulting pups
were screened for the Min mutation [38] and for the
Vash2−/− gene by PCR [19,39]. Mice were maintained in
air-filtered clean rooms and fed sterilized standard la-
boratory chow and water ad libitum. Because it has been
previously shown that a combination of a high-fat diet
and dextran sodium sulfate strongly promotes intestinal
carcinogenesis in ApcMin/+ mice [24,25,40], the animals
Figure 7 (See legend on next page.)
Kitahara et al. Molecular Cancer 2014, 13:99 Page 10 of 15
http://www.molecular-cancer.com/content/13/1/99
(See figure on previous page.)
Figure 7 Immunohistochemical analysis of tumor vessels in ApcMin/+ and ApcMin/+/Vash2−/− mice. A, Double staining for CD31 and LYVE1
in intestinal polyps from ApcMin/+ mice and ApcMin/+/Vash2−/− mice at 16 weeks of age. Scale bar: 100 μm. n = 3. B, Double staining for CD31 and
Desmin of tumor vessels in intestinal polyps from ApcMin/+ mice and ApcMin/+/Vash2−/− mice. Note the pericytes were detached from endothelia
in ApcMin/+ mice, whereas they returned to cover vessel walls in ApcMin/+/Vash2−/− mice. Scale bar: 10 μm, n = 3. C, Semi-thin section stained
with toluidine blue and CD31. Pericyte coverage of normal tumor vessels was found in tumors of ApcMin/+/Vash2−/− mice. Asterisks, endothelial
cells. Arrowheads, pericytes. Scale bars: 10 μm, n = 3. D, Ratio of pericyte coverage. Open columns represent ApcMin/+ mice and closed columns
represent ApcMin/+/Vash2−/− mice. Pericytes per blood vessel was estimated by counting semi-thin section in 3 separate fields of tumor lesions in
ApcMin/+ mice and ApcMin/+/Vash2−/− mice at a magnification of × 1000. **P < 0.01, n = 3.
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Japan) and 2% DSS (Tokyo Chemical Industry, Tokyo,
Japan) to ensure development of adenomas and adeno-
carcinomas in the small intestine 3 months later. The
Animal Experiment Committee, Tokyo Women’s Medical
University (TWMU) approved the procedures employed
in the handling and study of the mice. The following ex-
periments were performed in accordance with legislation
of the Institute of Laboratory Animals for Animal Experi-
mentation at TWMU. Unless otherwise stated, at least 20
mice in each experimental group were examined.
Cell culture
CMT93 cells [41] derived from a mouse rectal carcin-
oma were obtained from the European Collection of Cell
Cultures (Sigma-Aldrich, St Louis, MO, USA). CMT93
cells were grown in Dulbecco’s modified Eagle medium
(DMEM: Invitrogen, Carlsbad, CA, USA) supplemented
with 10% heat-inactivated fetal bovine serum, 5 × 10−5 M
2-mercaptoethanol, 10 mM HEPES, 1 mM sodium pyru-
vate, 3.75 g/L NaHCO3, 2 mM glutamine, 100 U/mL
penicillin, and 0.1 mg/mL streptomycin (Gibco, Grand
Island, NY, USA). CMT93 tumor cells (2.5 × 106 cells) in
250 μL of calcium- and magnesium-free phosphate-
buffered saline (Ca++-, Mg++-free PBS; pH 7.4) wereFigure 8 Tomato lectin staining of functional tumor vessels in gastro
staining of functional tumor vessels in polyps. Double staining for tomato l
staining for tomato lectin and CD31 staining of tumor vessels in hyperplast
less vascularized than hyperplastic lesions in the gastrointestinal tract. Scale
tomato lectin+ blood vessels in 5 separate fields of hyperplastic or tumor le
*P < 0.05, n = 3.injected into the dorsal subcutis (s.c.) of WT C57BL/6
mice and Vash2−/− mice.
Definition of adenomas and adenocarcinomas
All tumors (early-stage: approximately 12 weeks or earl-
ier, late-stage: approximately 16 weeks or later) that de-
veloped in mice were examined in paraffin sections
stained with H&E, and histopathological changes such
as carcinoma in situ and stromal invasion were evalu-
ated. Tumors were diagnosed as adenomas by expansion
to the mucosal layer, reduction of goblet cell numbers,
and moderate loss of mucosal architecture by glandular
growth and dilated cysts. Adenomas with 50% of high-
grade dysplasia (severe distortion of the glandular archi-
tecture and prominent atypical cells) were considered
carcinomas in situ. However, only the lesions showing
invasion through the lamina muscularis mucosae were
identified as adenocarcinomas.
General tissue preparation
All mice were anesthetized by an intramuscular (i.m.) in-
jection of ketamine (87 mg/kg) and xylazine (13 mg/kg).
Under deep anesthesia, the chest was opened and the
aorta was perfused with 4% paraformaldehyde (PFA) in
PBS for 10 min at a pressure of 120 mm Hg using anintestinal polyps from ApcMin/+/Vash2−/− mice. A, Tomato lectin
ectin and CD31 staining of tumor vessels in tumor lesions (a). Double
ic lesions (b). Note the tumor lesions in ApcMin/+/Vash2−/− mice were
bars, 100 μm. B, MVD was estimated by measuring the total area of
sions in ApcMin/+/Vash2−/− mice at a magnification of × 400.
Table 1 Changes in tumor microvasculature during multistep carcinogenesis
Apc mice
Adenoma-carcinoma
sequence:
Normal
tissue
Adenoma Adenoma Adeno Ca
(early) (late)
Morphological abnormality;
Vessel density − 1+ 2+ 3+
Lumen Round Not round Not round Not round
Systematic Tortuous Tortuous Tortuous
Branching − 1+ 2+ 3+
Irregularity − 2+ 3+ 3+
Ec
Morphology Normal Protuberance Protuberance Protuberance
Microvilli Microvilli Microvilli
IHC Lectin + + + +
CD31 + + + +
CD105 − ± + +
BM
Morphology Single Multiple Multiple Multiple
Pc
Morphology Attached Detached Detached Detached
Protuberance Protuberance Protuberance
IHC Desmin + + + +
α-SMA − − ± +
Pv
IHC VASH2 − − + +
Functional abnormality;
Permeability − − + ++
Blood flow (lectin) Normal Irregularity 1+ Irregularity 2+ Irregularity 2+
Hypoxia (HIF1-α) − − ± +
Gene mutation Apc Apc K-ras p53 and more
Stage of microvasculature Stage 0 Stage I Stage IIa Stage IIb
Apc: ApcMin/+, Ec: Endothelial cell, BM: Basement membrane, Pc: Pericyte, Pv: Peripheral tumor vessel, IHC: Immunohistochemistry. Samples were scored as negative
(−), mild (1+), Moderate (2+), Severe (3+). Positive staining was recorded as absent (−), weak (±), positive (+), strong (++).
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blood and fixative were then flushed out through an
opening in the right atrium. After perfusion, tissues were
removed, cut into small pieces and rinsed in PBS, then
further immersed in PBS containing a graded series of
sucrose (up to 30%) at 4°C overnight. Subsequently,
these tissues were embedded in Tissue-Tek O.C.T. com-
pound (Sakura Finetek, Torrance, CA, USA) and snap-
frozen in liquid nitrogen. Cryostat sections (14–120 μm)
were cut, placed on silane-coated glass slides, air-dried
for at least 2 h and then immunostained.
To obtain semi-thin Epon-embedded sections, various
tissues were excised, cut into small blocks, and fixed by
immersion in 2% glutaraldehyde in 0.1 M phosphate buf-
fer (PB; pH 7.2) at 4°C for 24 h. After washing out thefixatives with 0.1 M PB, the blocks were treated with 1%
osmium tetroxide (OSO4)-0.1 M PB (a mixture of 2%
OsO4 + 0.2 M PB). The tissues were dehydrated in a
graded series of ethanol, infiltrated with propylene oxide,
and embedded in Epon. Semi-thin sections (0.5 μm thick)
were made and stained with 1% toluidine blue in PBS.
Labeling of blood vessels with tomato lectin for 3d
imaging
To identify blood vessels, we used the intravascular perfusion of
fluorescent tomato lectin to label all blood-circulating vessels
[42]. Briefly, under anesthesia, the mice were intravenously (i.v.)
injected with 100 μl of FITC-conjugated tomato lectin (Lycoper-
sicon esculentum lectin; 1 mg/mL; Vector Labs, Burlingame,
CA). Tomato lectin binds uniformly to the luminal surface of
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patent blood supply. After perfusion, the tissues were processed
for subsequent analyses as described above.Immunohistochemistry
Cryosections were first incubated in 4% Block Ace
(Dainippon Seiyaku, Osaka, Japan) to block nonspecific
background stains, and successively incubated with vari-
ous primary antibodies (alone or in combination) in PBS
containing 1% bovine serum albumin (Sigma-Aldrich, St
Louis, MO, USA) at 4°C overnight. ECs were identified
with antibodies to CD31 (PECAM-1; hamster monoclo-
nal, 1:400; Chemicon, Billerica, MA, USA) and Von
Willebrand Factor (vWF; rabbit polyclonal antibody; dilu-
tion, 1:100; DakoCytomation, Glostrup, Denmark). The
basement membrane was identified with an antibody
against mouse type IV collagen (rabbit polyclonal 1:1000;
Cosmo Bio, Tokyo, Japan). Pericytes were identified with
antibodies to α-smooth muscle actin (Cy3-conjugated
mouse monoclonal, 1:500; Sigma-Aldrich) and desmin
(rabbit polyclonal, 1:200, Abcam, Cambridge, MA, USA).
VASH2-expressing cells were labeled with a rabbit poly-
clonal antibody to mouse VASH2 [19] (1:100; a generous
gift from the Institute of Development, Aging and Cancer,
Tohoku University, Sendai, Japan). After several washes
with PBS, specimens were incubated with combinations
of fluorescent (FITC, Cy3, and Cy5)-conjugated anti-
rat, −hamster, and -rabbit secondary antibodies
(Jackson ImmunoResearch, West Grove, PA, USA) for 2 h
at room temperature. Immunostained sections were ex-
amined using a Leica TCS-SL confocal laser-scanning
microscope (Leica Microsystems, Wetzlar, Germany).Immunolabeling of semi-thin sections
After thawing and air-drying, cryosections were rehy-
drated in PBS then incubated with 4% Block Ace
blocking solution (Dainippon Seiyaku, Tokyo, Japan) to
reduce nonspecific background staining. For ordinary
immunoenzymatic staining, tissue sections were incu-
bated with anti-CD31 overnight at 4°C. The sections
were further incubated with goat anti-rat immunoglobu-
lins labeled with horseradish peroxidase (HRP) (GE
Healthcare UK, Buckinghamshire, UK; 1:100 in PBS with
1% heat-inactivated normal mouse serum) for 2 h. The
HRP reaction was developed at RT for 20 min in a solu-
tion of 10 mg of 3′-diaminobenzidine hydrochloride
(DAB: Dojin Chemicals, Kumamoto, Japan) in 30 ml of
PBS with 10 μg of 30% H2O2. Sections were washed in
distilled water. After the DAB reaction, the sections were
fixed in 2.5% glutaraldehyde in PB at 4°C for 1 h and
subsequently in 2% osmium tetroxide in PB at room
temperature for 1 h. They were then dehydrated in a
graded series of ethanol and embedded in an epoxyresin. Semi-thin sections stained with 0.05% toluidine
blue were examined using a light microscope.Morphometric analysis
For analyses of the microvessel density (MVD), the total
areas of CD31, vWF-positive capillaries, and venules
were assessed by scanning tumor sections under × 40
magnification and counting in 10 random fields under ×
600 magnification [44,45]. Pericytes were identified by
scanning tumor sections under × 1000 magnification and
counting in 3 random fields under × 1000 magnification
[46]. These data were analyzed using a BZ-Analyzer
(Keyence, Osaka, Japan).Human tissue samples
Surgical specimens were obtained from 10 patients with
colorectal adenoma (n = 5) or adenocarcinoma (n = 5)
who underwent proctocolectomies in the Department of
Surgery at Nishiarai Hospital (Tokyo, Japan) between
April 2010 and March 2011. Patients with additional
cancers were excluded. The Clinical Pathology Depart-
ment of the Nishiarai hospital confirmed the histopatho-
logical diagnosis. Written informed consent was obtained
from all patients for the surgery and for the use of their
resected samples. H&E staining was performed to deter-
mine the histologic tumor type, lymphatic invasion, and
vascular invasion in all specimens.Western blot analysis
Tissue and cell samples were lysed in SDS sample buffer,
separated in 10% SDS-acrylamide gels, and electrotrans-
ferred to nitrocellulose membranes. After blocking with
5% non-fat dry milk in TBST buffer (10 mmol/L Tris–
HCl (pH 8.0), 150 mmol/L NaCl, 0.05% Tween 20),
the nitrocellulose membranes were probed with anti-
CD31 (1:200; Santa Cruz Biotechnology, Santa Cruz,
CA, USA), anti-VEGF (1:1,000; R&D Systems, MN,
USA), anti-VEGF (1:1,000; R&D Systems, MN, USA),
anti-CEA (1:2,000; Santa Cruz Biotechnology), anti-
CA19-9 (1:2,000; Santa Cruz Biotechnology), anti-KRAS
(1:2,000; Abcam, Cambridge, MA, USA), anti-p53
(1:1,000; R&D Systems), and anti-α-tubulin (1:1,000;
Santa Cruz Biotechnology) antibodies, followed by incu-
bation with HRP-conjugated anti-rabbit or anti-rat im-
munoglobulin G secondary antibodies (1:2,000; Jackson
ImmunoResearch). The antibody binding was then
visualized with enhanced chemiluminescence reagents
(GE Healthcare, Amersham, UK), and the band images
detected using the LAS3000 system (Fuji Film, Tokyo,
Japan) were densitometrically analyzed using Image
Gauge (Fuji Film).
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Total RNA was extracted using QIAzol Lysis Reagent
(Qiagen, Venlo, Netherlands). First-strand cDNA was
generated using ReverTra Ace (Toyobo, Osaka, Japan).
Quantitative real-time RT-PCR was performed using
the CFX96 real-time PCR detection system (Bio-Rad
Laboratories, Hercules, CA, USA) according to the man-
ufacturer’s instructions. PCR conditions consisted of an
initial denaturation step at 95°C for 3 min, followed by
40 cycles of 10 s at 95°C, 10 s at 56°C, and 30 s at 72°C.
Relative mRNA levels of target genes were normalized to
the beta-2-microglobulin (B2m) mRNA level. The primer
pairs used were as follows: mouse B2m forward,
5′-GGTCTTTCTGGTGCTTGTCTCA-3′, and reverse,
5′-GTTCGGCTTCCCATTCTCC-3′; mouse CD31 for-
ward, 5′-TTCAGCGAGATCCTGAGGGTC-3′, and re-
verse, 5′-CGCTTGGGTGTCATTCACGAC-3′; mouse
CD105 forward, 5′-TACAGTGCATCGACATGGAC-3′,
and reverse, 5′- TCAGAGGTCAATGGAGACAC-3′;
mouse Vegfa forward, 5′-AGAGAGCAACATCACCAT
GC-3′, and reverse, 5′- TCTGAACAAGGCTCACAG
TG-3′; mouse Vash2 forward, 5′-GGACATGCGGATGA
AGATCT-3′, and reverse, 5′- CTAGATCCGGATCTGAT
AGC-3′.
X-gal staining
Frozen sections were incubated in the dark for 18 h at
37°C in X-gal solution containing 1 mg/mL 5-bromo-
4chloro-3-indolyl-β-D-galactoside (X-Gal, Gene Therapy
Research Reagents, San Diego, CA, USA).
Transmission electron microscopy
Anesthetized mice were fixed by vascular perfusion of 4%
PFA and 2.5% glutaraldehyde in 0.1 M sodium cacodylate
buffer (100 mL; pH 7.4) at a pressure of 120 mmHg. Im-
mediately after the perfusion, the tumor tissues were re-
moved, cut into small pieces, and immersed in the same
fixative for another 2 h at 4°C. Specimens were then
treated with 1% OSO4 for 2 h at 4°C, and then with satu-
rated uranyl acetate for 3 h at room temperature. There-
after, specimens were dehydrated in a graded series of
ethanol and embedded in epoxy resin. Ultrathin sections
(70 nm thick) were made, counterstained with saturated
uranyl acetate followed by lead citrate, and observed using
a Hitachi H-7000 electron microscope (Hitachi High-
Technologies Co., Tokyo, Japan).
Statistics
All results are expressed as mean ± standard deviation
(SD). The statistical significance of differences was deter-
mined using the one-tailed Student’s t-test. The differ-
ence between two values was considered statistically
significant if the P value was less than 0.05, and as highly
significant if the P value was less than 0.01.Additional files
Additional file 1: Figure S1. Expression of endothelial makers and
angiogenic factors in normal intestinal tissue and intestinal polyp tissue
as determined by quantitative RT-PCR. Total RNA was isolated and
examined for CD31, CD105, and Vegfa expression. Data for all samples
were normalized to Gapdh and expressed as relative ratios to wild-type
(WT) controls. Note the increase in CD31 and CD105 levels in benign
tumors in ApcMin/+ mice. WT, normal small intestine in C57BL/6 mice
(white columns); Apc, normal small intestine in ApcMin/+ mice (slashed
columns); Apc tumor 12 w, early stage (around 12 weeks) adenoma in
ApcMin/+ mice (gray columns); Apc tumor 20 w, late stage (later than
20 weeks) adenoma or adenocarcinoma (black columns). *P < 0.05, n = 3.
Additional file 2: Figure S2. Expression of Vash2 in CMT93 tumor cells
as determined by quantitative RT-PCR. Total RNA was isolated and Vash2
expression assessed. Data for all samples were normalized to Gapdh and
are expressed as ratios relative to wild-type (WT) controls. n = 3.Abbreviations
α-SMA: α-smooth muscle actin; ECs: Endothelial cells; HCCs: Hepatocellular
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